Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Larotrectinib Likely to Get EU Nod for NTRK+ Tumors

July 26th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Turning to Broad Sequencing Panels for Targeted Therapy in Advanced NSCLC

July 26th 2019

Mohammad Razaq, MD, discusses how the detection of driver mutations has changed the way treatment is approached in advanced non–small cell lung cancer.

The Future Treatment Landscape of AML

July 22nd 2019

Targeting IDH1/2 in AML

July 22nd 2019

Relapsed vs. Refractory Data for FLT3 Inhibitors in AML

July 22nd 2019

Data Supporting Quizartinib in FLT3+ R/R AML

July 22nd 2019

Targeting FLT3 in Patients with Relapsed/Refractory AML

July 22nd 2019

Recent Data on the Treatment of Older Patients With AML

July 22nd 2019

Management of Adverse Events in Older Patients With AML

July 22nd 2019

Role of Hypomethylating Agents in AML

July 22nd 2019

Treatment of AML With Myelodysplasia-Related Changes

July 22nd 2019

Role of Maintenance Therapy in AML

July 22nd 2019

Consolidation Strategies in AML

July 22nd 2019

Treatment Strategies and Patient Specific Factors in AML

July 22nd 2019

MRD Assessment and its Clinical Implications in AML

July 22nd 2019

Prognostic Significance of MRD in AML

July 22nd 2019

Therapeutic Approaches Based on Mutations in AML

July 22nd 2019

Best Practices for NGS Testing in AML

July 22nd 2019

Genetic Alterations in Acute Myeloid Leukemia

July 22nd 2019

Treatment of NSCLC With RET Fusions

July 19th 2019